Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab Combination With Chidamide in Patients With Recurrent and Refractory Diffuse Large B-Cell Lymphoma
NCT06570447Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Small Molecules, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab, tucidinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Feb 2025; status: recruiting.
02
Drugs
glofitamabtucidinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06570447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06570447.